- Home
- OLMA
as 11-15-2024 3:38pm EST
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 525.7M | IPO Year: | 2020 |
| Target Price: | $27.00 | AVG Volume (30 days): | 417.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.51 - $17.10 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Olema Pharmaceuticals Inc. News
OLMA Breaking Stock News: Dive into OLMA Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
11 days ago
Olema Oncology to Participate in Upcoming Investor Conferences
GlobeNewswire
13 days ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
17 days ago
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
GlobeNewswire
25 days ago
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
GlobeNewswire
a month ago
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
GlobeNewswire
a month ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare OLMA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OLMA Olema Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.